Table 1.
Chemokine | Concentration | ‐fold increase in migration | Cell type | Assay | ECM component | Reference |
---|---|---|---|---|---|---|
HGF | 10 ng/ml | 5.43‐; 5‐ | Primary myoblasts (rat; human) | Transwell | Fibronectin | Bischoff (1997), González et al (2017) |
SDF‐1 | 10 ng/µl | 2.5‐ | Primary myoblasts (mouse) | Wound healing | Uncoated | Kowalski et al (2017) |
TGF‐β | 5 ng/ml; 20 ng/ml | 4.42‐; 0.73‐ | Primary myoblasts (rat); C2C12 myoblasts | Transwell; wound healing | Fibronectin; uncoated | Bischoff (1997), Leloup et al (2006) |
IGF‐1 | 40 ng/ml; 100 ng/ml | 0.66‐; 3.4‐ | C2C12 myoblasts; primary myoblast (mouse) | Wound healing; transwell | Uncoated | Leloup et al (2006), Yanagiuchi et al (2009) |
Insulin | 15 µg/ml | 0.97‐ | C2C12 myoblasts | Wound healing | Uncoated | Leloup et al (2006) |
FGF‐2 | 1 ng/ml; 10 ng/ml; 10 ngml; 100 ng/ml; 3.8–7.0 ng/ml | N/A; 7.8‐; 6.4‐ ; 3.4‐; N/A | Primary myoblasts (rat; mouse‐embryonic; mouse; mouse; human) | Transwell; Blind well chemotaxis chamber; Chemotaxis chamber; Chemotaxis chamber; Microfluidics device | Fibronectin; Uncoated; Fibronectin; Uncoated; Uncoated; | Bischoff (1997), Webb et al (1997), Neuhaus et al (2003), Yanagiuchi et al (2009), Ferreira et al (2015) |
FGF‐4 | 10 ng/ml | 6.7‐ | Embryonic myoblasts (mouse) | Blind well chemotaxis chamber | Uncoated | Webb et al (1997) |
FGF6 | 10 ng/ml | ~5‐ | Primary myoblasts (mouse) | Chemotaxis chamber | Fibronectin | Neuhaus et al (2003) |
PDGF‐BB | 50 ng/ml | 3.3‐ | Primary myoblasts (human) | Transwell | Uncoated | Piñol‐Jurado et al (2017) |
5% Chick embryo extract | N/A | 6.7‐ | Primary myoblasts (rat) | Transwell | Fibronectin | Bischoff (1997) |
In cases where multiple concentrations were assessed, the concentration that facilitated the greatest fold change of migration was taken.